Published in N Engl J Med on May 09, 1991
Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med (2011) 3.82
How I treat acquired aplastic anemia. Blood (2012) 2.44
High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood (2009) 2.25
Aplastic anemia. Curr Opin Hematol (2008) 2.17
Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood (2010) 1.91
Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica (2009) 1.73
STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood (2013) 1.59
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol (2008) 1.49
Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis (2011) 1.16
In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia. Haematologica (2014) 1.08
Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica (2011) 1.07
Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood (2011) 1.04
Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. Biol Blood Marrow Transplant (2010) 0.98
Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors. Am J Hematol (2015) 0.86
Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant (2010) 0.83
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol (2012) 0.83
Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemia. Am J Pathol (2006) 0.82
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med (2017) 0.82
Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-gamma. Immunology (1994) 0.81
Pathophysiology and treatment of aplastic anemia. Wien Klin Wochenschr (2003) 0.81
Recent advances in treatment of aplastic anemia. Korean J Intern Med (2014) 0.81
Identification of novel regulators in T-cell differentiation of aplastic anemia patients. BMC Genomics (2006) 0.80
Opportunistic infections and CD4+ T-lymphocytopenia without HIV infection: report of two cases. CMAJ (1993) 0.79
Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A. J Cancer Res Clin Oncol (2003) 0.79
Worsening bradycardia following antithymocyte globulin treatment of severe aplastic anemia. J Pediatr Pharmacol Ther (2011) 0.78
Outcomes of optimized over standard protocol of rabbit antithymocyte globulin for severe aplastic anemia: a single-center experience. PLoS One (2013) 0.78
Aplastic anemia: immunosuppressive therapy in 2010. Pediatr Rep (2011) 0.77
Anemia of Central Origin. Semin Hematol (2015) 0.76
Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning. J Immunol (2016) 0.75
Immunosuppression in aplastic anemia--postponing the inevitable? N Engl J Med (1991) 0.75
Presentation and Management of Paroxysmal Nocturnal Hemoglobinuria: A Single-Center Experience. Hematol Rep (2016) 0.75
Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II. Ann Hematol (2016) 0.75
Immune suppression therapy in aplastic anemia: influencing factors on response and survival. Korean J Intern Med (1995) 0.75
Human embryonic stem cell therapy for aplastic anemia. Clin Case Rep (2017) 0.75
Incidence and outcome of acquired aplastic anemia-real-world data from patients diagnosed in Sweden from 2000-2011. Haematologica (2017) 0.75
T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells. J Exp Med (1988) 3.90
Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Lancet (1994) 3.24
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res (1996) 2.86
Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med (1994) 2.78
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood (1994) 2.78
Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest (1999) 2.34
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2000) 2.19
Mechanisms underlying FeCl3-induced arterial thrombosis. J Thromb Haemost (2011) 2.18
Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood (1994) 2.16
Post-transcriptional regulation of interleukin-6 gene expression in human keratinocytes by ultraviolet B radiation. J Invest Dermatol (1994) 2.09
Congenital dyserythropoietic anemia with karyorrhexis and multinuclearity of erythroblasts. Helv Med Acta (1968) 2.02
Acute pancreatitis and normoamylasemia. Not an uncommon combination. Ann Surg (1989) 1.94
Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med (1985) 1.87
NEW PENETRATING VEHICLES AND SOLVENTS. Science (1942) 1.86
Neuronal expression of the NADPH oxidase NOX4, and its regulation in mouse experimental brain ischemia. Neuroscience (2005) 1.84
Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med (1999) 1.79
Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood (1989) 1.74
Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J Thromb Haemost (2003) 1.72
Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab (1998) 1.70
Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am (2000) 1.69
Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood (1988) 1.69
Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). Br J Haematol (2001) 1.66
Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med (1999) 1.65
Expression of an X-linked muscular dystrophy in a female due to translocation involving Xp21 and non-random inactivation of the normal X chromosome. Hum Genet (1984) 1.64
High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia. Blood (1989) 1.64
Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia (2004) 1.64
Restriction and modification in Bacillus subtilis: identification of a gene in the temperate phage SP beta coding for a BsuR specific modification methyltransferase. Mol Gen Genet (1980) 1.62
Disappearance rate of spermatozoa from the ejaculate following vasectomy. Fertil Steril (1969) 1.61
Normal values for respiratory resistance using forced oscillation in subjects>65 years old. Eur Respir J (2005) 1.61
Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol (2001) 1.59
Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med (1992) 1.59
Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. Semin Hematol (2000) 1.59
A revised model of platelet aggregation. J Clin Invest (2000) 1.54
The effect of the diameter of metal-on-metal bearings on systemic exposure to cobalt and chromium. J Bone Joint Surg Br (2006) 1.52
Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol (1994) 1.51
Granulocyte/macrophage colony-stimulating factor induces interleukin 1 production by human polymorphonuclear neutrophils. J Immunol (1988) 1.51
Mesenchymal stem cells for clinical application. Vox Sang (2009) 1.50
Immunoadsorption patients with multiple sclerosis: an open-label pilot study. Eur J Clin Invest (2005) 1.50
Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant (2007) 1.47
Selective advantage of fra (X) heterozygotes. Hum Genet (1990) 1.47
Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int (2002) 1.47
Altered surface marker expression and function of G-CSF-induced neutrophils from test subjects and patients under chemotherapy. Br J Haematol (1994) 1.45
Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. J Pathol (2005) 1.45
The sequence complementarity between HIV-1 5' splice site SD4 and U1 snRNA determines the steady-state level of an unstable env pre-mRNA. RNA (2001) 1.42
A point mutation in a type I procollagen gene converts glycine 748 of the alpha 1 chain to cysteine and destabilizes the triple helix in a lethal variant of osteogenesis imperfecta. J Biol Chem (1987) 1.41
Transcript synthesis and surface expression of the interleukin-2 receptor (alpha-, beta-, and gamma-chain) by normal and malignant myeloid cells. Blood (1996) 1.40
Headache after hematopoietic stem cell transplantation: being aware of chronic bilateral subdural hematoma. Leuk Lymphoma (2006) 1.40
Young investigators. FASEB J (1990) 1.40
[Severe tetraparesis as the first manifestation of a chronic lymphatic leukemia]. Dtsch Med Wochenschr (1992) 1.39
The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT/3 and other cytokine-inducible nuclear proteins. Mol Cell Biol (1996) 1.38
[Fall Congress for Integrative Medicine--model for the future]. Dtsch Med Wochenschr (2009) 1.38
Community-acquired pneumonia in older patients. J Am Geriatr Soc (1996) 1.37
Retracted Granulocyte-macrophage colony-stimulating factor induces cytokine secretion by human polymorphonuclear leukocytes. J Clin Invest (1989) 1.37
T lymphocyte activation by staphylococcal enterotoxins: role of class II molecules and T cell surface structures. Cell Immunol (1989) 1.36
Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant (2006) 1.36
The inhibition of the motility of human spermatozoa by various pharmacologic agents. Biol Reprod (1975) 1.35
Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant (1994) 1.33
Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood (1989) 1.33
Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet (1983) 1.31
Tumor necrosis factor (TNF)-alpha but not TNF-beta induces secretion of colony stimulating factor for macrophages (CSF-1) by human monocytes. Blood (1987) 1.31
Congenital dyserythropoietic anaemia, types I and II: aberrant pattern of erythrocyte membrane proteins in CDA II, as revealed by two-dimensional polyacrylamide gel electrophoresis. Br J Haematol (1977) 1.30
How much blood is needed? Vox Sang (2011) 1.30
Effects of (H + ), (Na + ), (K + ) and certain membrane-active drugs on glycolysis, motility, and ATP synthesis by human spermatozoa. Biol Reprod (1973) 1.28
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia (2004) 1.28
Function of the CD4 and CD8 molecules on human cytotoxic T lymphocytes: regulation of T cell triggering. J Immunol (1986) 1.27
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
Neonatal stroke involving the middle cerebral artery in term infants: clinical presentation, EEG and imaging studies, and outcome. Dev Med Child Neurol (1995) 1.24
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol (2005) 1.22
High levels of thrombopoietin in sera of patients with essential thrombocythemia: cause or consequence of abnormal platelet production? Ann Hematol (1998) 1.21
DEMONSTRATING THE PRESENCE OF SULFONAMIDES IN THE TISSUES. Science (1943) 1.20
Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med (2001) 1.19
Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest (1987) 1.18
Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation (2001) 1.17
High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol (2010) 1.17
Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol (1984) 1.17
Expression and regulation of myeloid-specific genes in normal and leukemic myeloid cells. Blood (1991) 1.17
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood (1993) 1.16
Classical Ehlers-Danlos syndrome caused by a mutation in type I collagen. Am J Hum Genet (2000) 1.16
Effects of site-directed mutagenesis of basic residues (Arg 94, Lys 95, Lys 99) of lipopolysaccharide (LPS)-binding protein on binding and transfer of LPS and subsequent immune cell activation. J Immunol (1996) 1.16
Restriction and modification in Bacillus subtilis: two DNA methyltransferases with BsuRI specificity. I. Purification and physical properties. J Biol Chem (1981) 1.15
Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type. Clin Exp Immunol (1982) 1.14
Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood (1989) 1.14
Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization. J Thromb Haemost (2009) 1.14
Electron and light microscopic study of the erythroblasts of patients with congenital dyserythropoietic anemia. Blood (1971) 1.14
GM-2 gangliosidosis (Sandhoff's disease): two year follow-up by MRI. Neuroradiology (1994) 1.14
Ionizing radiation induces expression of interleukin 6 by human fibroblasts involving activation of nuclear factor-kappa B. J Biol Chem (1993) 1.13
Human X chromosome markers and Duchenne muscular dystrophy. Nucleic Acids Res (1985) 1.13
ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Blood (2000) 1.12